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Abstract
Introduction: The effector functions of immunoglobulin G (IgG) are mediated by interaction of its Fc region with
Fc receptors (FcgRs) and/or the complement system. The three main pathways of complement activation converge
at C3. However, C3-independent pathways can activate C5 and other downstream complement components
during IgG-initiated inflammatory responses. These C3-independent pathways of C5 activation are triggered by
activating FcgRs in some systems or can be activated by factors of the coagulation cascade such as thrombin. Here
we studied the interplay of C3, C5, and activating FcgRs in a model of spontaneous autoantibody-driven arthritis.
Methods: We utilized the K/BxN TCR transgenic mouse model of arthritis. We bred K/BxN mice bearing targeted or
naturally-occurring mutations in one or more of the genes encoding complement components C3, C5, and FcRg,
the cytoplasmic signaling chain shared by the activating FcgRs. We measured arthritis development, the production
of arthritogenic autoantibodies, T cell activation status and cytokine synthesis. In addition, we treated mice with
anti-C5 monoclonal antibodies or with the thrombin inhibitor argatroban.
Results: We have previously shown that genetic deficiency of C5 protects K/BxN mice from the development of
arthritis. We found here that C3-deficient K/BxN mice developed arthritis equivalent in severity to C3-sufficient
animals. Arthritis also developed normally in K/BxN mice lacking both C3 and FcRg, but could be ameliorated in
these animals by treatment with anti-C5 monoclonal antibody or by treatment with argatroban. Production of
arthritogenic autoantibodies, T cell activation, and T cell cytokine production were not affected by the absence of
C3, C5, and/or FcRg.
Conclusions: In K/BxN mice, C5-dependent autoantibody-driven arthritis can occur in the genetic absence of both
complement C3 and activating FcgRs. Our findings suggest that in this setting, thrombin activates C5 to provoke
arthritis.
Introduction
The ability of immunoglobulin and immune complexes,
including autoantibodies, to provoke inflammation
stems from the interaction of the Fc portion of antibody
molecules with one or both of two major effector path-
ways: Fc receptors and the complement system. The
relative contributions of these two pathways vary among
different disease states and experimental systems [1-3].
A more detailed understanding of the mechanisms by
which autoantibodies engage Fc receptors and
complement to provoke pathology in a specific target
tissue can permit a more tailored therapeutic
intervention.
Fcg receptors (FcgRs) recognize immunoglobulin G
(IgG) and transduce either activating or inhibitory intra-
cellular signals. In the mouse, the activating FcgRs
include FcgRI, FcgRIII, and FcgRIV. The activating FcgRs
share a common cytoplasmic signaling chain called FcRg
(encoded by the Fcer1g gene) responsible for signal
transduction. Mice also express the inhibitory receptor
FcgRIIB, whose cytoplasmic tail contains an inhibitory
signaling motif. The outcome of an interaction of an
FcgR-expressing cell with an IgG-containing immune
complex depends on the relative expression levels of the
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various activating and inhibitory FcgRs and also the IgG
subtype (for which the various FcgRs have differing affi-
nities) [4].
The complement system is activated by three primary
pathways (classic, alternative, and mannose-binding-lec-
tin), each consisting of a series of serine proteases.
These three activation pathways converge at comple-
ment component C3. Cleavage of complement C3 pro-
duces a C5 convertase. These events result in the
generation of anaphylatoxins (for example, C3a and
C5a) and formation of the membrane attack complex
(C5b-9), whose main functions are to recruit inflamma-
tory cells and to mediate cellular lysis, respectively (Fig-
ure 1) [5,6].
Several studies have pointed to the existence of addi-
tional, C3-independent mechanisms by which C5 can be
activated to drive inflammatory responses (Figure 1).
More than two decades ago, investigators described the
existence of C5-C9-dependent immune hemolysis occur-
ring in a C3-independent fashion [7,8]. More recently,
studies of IgG-triggered acute lung injury revealed that,
in C3-deficient mice, thrombin can act as a C5 conver-
tase to generate C5a and mediate pathology [9]. Similar
crosstalk between the complement system and coagula-
tion systems has been identified in other model systems,
including antiphospholipid antibody-induced and lipo-
polysaccharide (LPS)-induced fetal loss in mice [10,11].
An elegant in vitro study has recently confirmed that
multiple serine proteases in the coagulation and fibrino-
lysis systems can cleave C3 and C5 to produce C3a and
C5a [12]. Interplay of FcgRs and the complement system
also occurs, and several studies of IgG-initiated pathol-
ogy have highlighted the existence of a C5a generation
pathway that is triggered by activating FcgRs [2,13-15].
Here, we investigated a possible contribution of C3-
independent mechanisms of C5 activation in a mouse
model of autoantibody-mediated arthritis.
K/BxN T-cell receptor (TCR) transgenic mice sponta-
neously develop inflammatory arthritis due to combined
T- and B-cell recognition of the self-antigen glucose-6-
phosphate isomerase (GPI) and production of high-titer
anti-GPI IgG autoantibodies [16,17]. Arthritis can also
be provoked by injecting serum from K/BxN mice into
normal mice [18]. Importantly, the requirements for
complement and activating FcgRs differ between the K/
BxN TCR transgenic mice and its derivative, the serum
transfer model, likely reflecting the several-fold higher
concentration of anti-GPI autoantibodies in the sponta-
neous genetic model. The development of serum-trans-
ferred arthritis depends on both activating FcgRs and
the alternative pathway of complement activation. Speci-
fically, mice with targeted or naturally occurring muta-
tions in the genes encoding factor B (of the alternative
pathway), C3, C5, the C5a receptor (C5aR), and FcRg
were protected from developing serum-transferred
arthritis [19-21]. In contrast, we have shown that K/BxN
TCR transgenic mice lacking FcRg developed sponta-
neous arthritis equivalently to controls but that C5-defi-
cient K/BxN mice developed less severe arthritis than
controls [22]. In addition, treating K/BxN mice with
anti-C5 monoclonal antibody reduced their arthritis
severity [22]. Those findings led us to investigate which




KRN TCR transgenic mice on the C57BL/6 (B6) back-
ground [16] were a gift from Diane Mathis and Chris-












Figure 1 Complement activation pathways. The three traditional complement activation pathways converge at complement component C3,
leading to the generation of a C5 convertase complex. Cleavage of C5 produces the anaphylatoxin C5a and C5b, initiating formation of the
C5b-9 membrane attack complex (MAC). The present study focuses on C3-independent C5 activation pathways shown on the left: activating
FcgRs and the coagulation cascade. FcgR, Fc receptor for immunoglobulin G.
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USA) and the Institut de Génétique et de Biologie Molé-
culaire et Cellulaire (Strasbourg, France). C5-deficient
B6 mice congenic for the non-obese diabetic (NOD)-
derived Hc allele (encoding non-functional C5) [22,23]
and B6 mice congenic for H-2g7 (B6.g7) were also a gift
from Mathis and Benoist; I-Ag7 is the mouse major his-
tocompatibility complex (MHC) class II molecule that
presents GPI-derived peptides to activate KRN TCR-
expressing T cells. C3-deficient mice on the B6 back-
ground [24] were a gift from Michael Carroll (Harvard
Medical School). FcRg (Fcer1g)-deficient mice on the B6
background [25] were purchased from Taconic (Hudson,
NY, USA).
The C3-, C5-, FcRg-, and double-deficient ‘K/BxN’
lines used in this study were created by breeding mice
bearing the appropriate knockout allele(s) on the B6
background to KRN/B6 mice and also to B6.g7 congenic
mice. The MHC (H2) is the only NOD-derived genetic
region that the B6.g7 mice retain; to simplify nomencla-
ture, however, we refer to the mice as ‘K/BxN’ through-
out this study as we have previously [22]. Because C3
and the H2 complex both reside on mouse chromosome
17, a spontaneous chromosomal recombination event
was necessary to generate C3-deficient B6.g7 congenic
mice. Genotyping of mice was performed by standard
polymerase chain reactions. Mice were bred in specific
pathogen-free colonies under protocols approved by the
University of Minnesota Institutional Animal Care and
Use Committee.
Antibodies
Anti-C5 monoclonal antibodies were derived from the
BB5.1 hybridoma, a gift from Brigitta Stockinger (MRC
National Institute for Medical Research, London, UK)
[26]. Antibodies used for flow cytometry included anti-
CD3 (clone 71A2), anti-CD44 (clone IM7), anti-CD62L
(clone MEL-14), anti-interleukin-17 (anti-IL-17) (clone
eBiol7B7), and anti-interferon-gamma (anti-IFNg) (clone
XMG1.2) from eBioscience (San Diego, CA, USA) and
anti-CD4 (clone RM4-5) and anti-Vb6 (clone RR4-7)
from BD Pharmingen (San Diego, CA, USA).
Assessment of arthritis, anti-C5 antibody treatment, anti-
GPI titers, histology, and immunohistochemistry
Assessment of arthritis severity by clinical score and
ankle thickening, treatment with anti-C5 antibody,
determination of anti-GPI IgG titers by enzyme-linked
immunosorbent assay, histological analysis, and immu-
nohistochemistry for C3 and IgG were performed as
described [22]. For detection of prothrombin, histologic
sections of mouse liver were first blocked by using the
avidin/biotin blocking kit (Invitrogen Corporation,
Carlsbad, CA, USA). Primary antibodies then were
added at a dilution of 1:20, in accordance with a prior
report [9]. The primary antibodies were goat polyclonal
IgG anti-thrombin (K20) or normal goat IgG (both from
Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA).
The primary antibodies were detected by secondary
staining with biotin-coupled donkey anti-goat IgG
diluted 1:2,000 (Santa Cruz Biotechnology, Inc.) followed
by application of ImmPACT DAB peroxidase substrate
with the ABC peroxidase kit (Vector Laboratories, Bur-
lingame, CA, USA).
Flow cytometry
Intracellular cytokine staining was performed in accor-
dance with the instructions of the manufacturer
(eBioscience). Flow cytometry was performed by using a
FACSCalibur and an LSRII (BD Biosciences, San Jose,
CA, USA), and cells were analyzed by using FlowJo V7.6
software (Tree Star, Inc., Ashland, OR, USA).
Argatroban treatment
Argatroban (Sigma-Aldrich, St. Louis, MO, USA) was
dissolved in dimethyl sulfoxide (DMSO) and injected
intraperitoneally into mice at a dose of 9 mg/kg daily or
five days per week fromthe ages of 3 to 6 weeks [27,28].
No differences were observed between those mice
receiving argatroban daily and those receiving it five
days per week, so the results were pooled for analysis.
The vehicle control-treated animals received DMSO
intraperitoneally.
Results and Discussion
We recently reported that K/BxN TCR transgenic mice
genetically lacking C5 or treated with anti-C5 monoclo-
nal antibodies developed less severe arthritis than con-
trol animals [22]. To determine which of the upstream
complement activation pathways were involved in
arthritogenesis, we first investigated complement com-
ponent C3, the convergence point for the three primary
complement activation pathways and the component
immediately upstream of C5. We bred K/BxN mice with
a targeted deletion in the C3 gene. In agreement with a
recent report, we observed that C3-deficient K/BxN
mice developed arthritis equivalently to littermate con-
trols (Figure 2) [29]. This finding suggested that a non-
traditional, C3-independent pathway of C5 activation
was at work in these mice.
Several reports have demonstrated that engagement of
activating FcgRs can trigger C5a production, even in the
absence of C3 [2,13-15]. We therefore hypothesized
that, in C3-deficient K/BxN mice, the absence of activat-
ing FcgRs would impair C5 production and lead to less
severe arthritis. To test this hypothesis, we bred K/BxN
mice genetically lacking both C3 and FcRg, the cytoplas-
mic signaling chain shared by the activating FcgRs. Sur-
prisingly, the C3/FcRg-double-deficient K/BxN mice
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developed arthritis of equivalent severity to controls
(Figure 3a). As expected, immunofluorescent staining of
joint sections from the C3/FcRg-deficient K/BxN mice
revealed IgG deposition similar to controls, but no C3
(Additional file 1a). Treatment of the C3/FcRg-deficient
K/BxN mice with anti-C5 monoclonal antibody reduced
their arthritis severity (Figure 3a). Considered together,
these findings indicate that, in the genetic absence of
C3, arthritis in K/BxN mice can be mediated by an











































Figure 2 Complement C3 deficiency has no effect on arthritis in K/BxN mice. The development of arthritis in K/BxN T-cell receptor
transgenic mice with a targeted deletion of C3 (open circles, n = 7 mice) and C3-sufficient littermate controls (filled circles, n = 8) was assessed
by arthritis score (a) and ankle thickening (b). Data are mean ± standard error of the mean. There are no statistically significant differences at
any of the time points.
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Figure 3 C5-mediated arthritis in K/BxN mice occurs in the absence of C3 and FcRg. (a) Null alleles of C3 and Fcer1g (encoding FcRg) were
bred into the K/BxN mouse system. The development of arthritis was assessed in C3/FcRg-deficient K/BxN mice bearing homozygous null alleles
at both loci (open squares, n = 4) and in littermate controls expressing one wild-type allele at each locus (filled squares, n = 4). Data are mean ±
standard error of the mean (SEM); there are no statistical differences at any of the time points for these two groups. Treatment of the C3/FcRg-
deficient K/BxN mice with anti-C5 antibody reduced arthritis severity (filled diamonds, n = 3); *P < 0.05 for the anti-C5 antibody-treated C3/FcRg-
deficient mice compared with untreated C3/FcRg-deficient mice. (b) A naturally occurring null allele of Hc (encoding C5) and the targeted null
allele of Fcer1g were bred into K/BxN mice. The development of arthritis was assessed in C5/FcRg-deficient K/BxN mice (open triangles, n = 8)
and in littermate controls with one wild-type allele at each locus (filled triangles, n = 8). Data are mean ± SEM; **P < 0.01; ***P < 0.001. FcRg, the
cytoplasmic signaling chain shared by activating Fc receptors for immunoglobulin G; NS, not significant.
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Consistent with our prior report that arthritis in K/
BxN mice depends on C5 but not FcRg [22], we found
that K/BxN mice lacking both C5 and FcRg developed
less severe arthritis than controls (Figure 3b). In the
ankles of these C5/FcRg-deficient K/BxN mice, deposi-
tion of both IgG and C3 was detectable, suggesting that
C3 deposition can still occur in the absence of C5 and
despite the less severe inflammatory response in these
joints (Additional file 1b). The fact that the C5/FcRg-
deficient mice developed some arthritis, albeit attenu-
ated, suggests that other minor pathogenic effector
mechanisms are still operational in these mice; candi-
date pathways include recognition of IgG immune com-
plexes by upstream complement components and their
receptors (for example, C1qR(P)/CD93 [30]), the pro-
inflammatory activity of C3a [6], and pathogenic effector
T cells.
We performed additional studies to determine how C5
deficiency interferes with arthritogenesis in K/BxN mice.
We found that the production of anti-GPI autoantibo-
dies was unimpaired in the C3-deficient, C3/FcRg-defi-
cient, and C5/FcRg-deficient K/BxN mice (Figure 4).
C5a was also recently shown to drive T helper 17
(Th17) cell differentiation in another murine arthritis
model [31]. Th17 cells are known to be involved in the
pathogenesis of arthritis in the K/BxN system [32,33].
We found, however, that T-cell activation as determined
by high expression of CD44 and low expression of
CD62L (Figure 5a) and the frequency of CD4+ T cells
producing the cytokines IFNg or IL-17 (Figure 5b) were
unaltered in the C5/FcRg-deficient K/BxN mice relative
to controls. Collectively, our findings indicate that the T
cell- and B cell-dependent events culminating in autoan-
tibody production and pro-inflammatory cytokine pro-
duction are not impacted by deficiency of C3, C5, and/
or FcRg and suggest that C5 drives arthritis in K/BxN
mice via downstream effector mechanisms. Given the
requirement of the C5aR but not the terminal comple-
ment components (C6-C9) for serum-transferred arthri-
tis [20], it is most logical that it is the interaction of C5a
with C5aR that drives arthritis in K/BxN mice, a
hypothesis that could be tested by generating C5aR-defi-
cient K/BxN mice. Next, we investigated how C5 was
being activated in the absence of C3 and activating
FcgRs.
Multiple lines of evidence point to molecular commu-
nications between the coagulation and complement cas-
cades, both of which contain numerous serine proteases.
Administration of the anticoagulant heparin blocked
antiphospholipid antibody-induced complement activa-
tion and pregnancy loss in a mouse model [10]. Simi-
larly, LPS increased the expression of the membrane-
bound prothrombinase FGL2, which can cleave C5 and
which also has been linked mechanistically to LPS-
induced abortions in mice [11,34]. In mice lacking C3,
the expression of prothrombin was upregulated, and
treatment of mice with anti-thrombin III blocked IgG-
induced C5-dependent lung injury [9]. We verified that
the expression level of prothrombin was increased in
the liver of C3-deficient mice relative to control mice
(Additional file 2). In keeping with this finding, treat-
ment of C3-deficient/FcRg-deficient K/BxN mice with
the thrombin inhibitor argatroban led to reduced arthri-
tis severity, and discontinuation of the argatroban was
temporally associated with the re-emergence of arthritis
(Figure 6). We are currently investigating longer-acting
compounds to determine whether thrombin inhibition
acts primarily to reduce arthritis severity or to delay the
onset of arthritis in this model. Thus, the generation of
C5 in the absence of C3 and activating FcgRs in K/BxN
mice appears to be mediated by thrombin or related ser-





































Figure 4 Absence of C3, C5, and FcRg does not impact autoantibody production in K/BxN mice. Serum levels of anti-GPI IgG were
determined in C3-deficient K/BxN mice and controls (left panel), C3/FcRg-deficient K/BxN mice and controls (middle panel), and C5/FcRg-
deficient K/BxN mice and controls (right panel). Control animals are indicated by filled bars and knockout mice by open bars. A405 indicates
absorbance in the enzyme-linked immunosorbent assay. Data are mean ± standard error of the mean. There are no statistically significant
differences between the anti-GPI levels. FcRg, the cytoplasmic signaling chain shared by activating Fc receptors for immunoglobulin G; GPI,
glucose-6-phosphate isomerase; IgG, immunoglobulin G.
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Whether C3-independent pathways of C5 activation
contribute to pathology in wild-type mice or only in the
setting of genetic C3 deficiency is important for under-
standing the relevance of these pathways to human dis-
eases. For instance, heparin was effective in reducing
antiphospholipid antibody-induced fetal loss in wild-type
mice by blocking C5a generation [10]. Similarly, treat-
ment with the thrombin inhibitor polyethyleneglycol-
hirudin (PEG-hirudin) decreased the severity of col-
lagen-induced arthritis in mice, although this was attrib-
uted to reductions in intra-articular fibrin deposition














Figure 5 T-cell activation and cytokine production are not affected by C5 and FcRg deficiency in K/BxN mice. (a) The plots depict cell
surface expression of CD44 and CD62L on CD3+ CD4+ Vb6+-gated splenocytes from the indicated mice. (b) Intracellular expression of the
cytokines interleukin-17 (IL-17) and interferon-gamma (IFNg) was detected in CD3+ CD4+ Vb6+ splenocytes from the indicated mice. Vb6 is the
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Figure 6 Thrombin inhibition ameliorates arthritis in C3/FcRg-deficient K/BxN mice. K/BxN mice lacking C3 and FcRg were treated with the
thrombin inhibitor argatroban (filled circles) or vehicle control (open circles) from 3 to 6 weeks of age. Treatment was then stopped. The
development of arthritis was determined by arthritis score (a) and twice weekly ankle measurements (b). Data plotted are mean ± standard
error of the mean and represent seven or eight mice per group compiled from three independent experiments. *P < 0.05, **P < 0.005, ***P <
0.001. FcRg, the cytoplasmic signaling chain shared by activating Fc receptors for immunoglobulin G.
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contrast, in the IgG-mediated lung injury model, the
effect of the anticoagulants anti-thrombin III and hir-
duin in reducing lung pathology was evident only in C3-
deficient animals, leading those investigators to specu-
late that genetic deficiency in C3 leads to upregulation
of thrombin as a compensatory mechanism to allow C5
activation via a non-traditional pathway [9]. Similarly,
we observed no effect of argatroban on arthritis severity
in C3-sufficient K/BxN mice (data not shown), but we
are currently exploring longer-acting thrombin inhibi-
tors. Thus, the contribution of the coagulation cascade
to C5 activation might vary depending on the disease
model. In addition, a recent report suggests that, in
vitro, thrombin cleaves C5 at a site different from that
cleaved by C5 convertase, leading to the generation of
novel intermediates [36]. Understanding whether these
intermediates are also generated in vivo and, if so, how
they affect inflammation will be essential next steps.
How IgG antibodies activate thrombin in the absence
of activating FcgRs and C3 remains an open and impor-
tant question. Since thrombin activation by IgG has
been observed in multiple autoantibody-dependent
models, it is not likely that the antigenic specificity is
critical. It seems more likely that other IgG-interacting
molecules (for example, complement C1q or the neona-
tal Fc receptor) could be at play. Alternatively, antibody
fragments with direct prothrombinase catalytic activity
have been described [37].
From a clinical perspective, monoclonal antibody
reagents designed to interfere with C5 activation sys-
temically or locally (for example, in the synovium)
might be effective treatments for inflammatory arthritis
(Figure 3a) [22,38,39]. Our findings suggest that agents
designed to interfere with non-traditional C5 activation
pathways such as the coagulation cascade might also
prove beneficial for treating inflammatory arthritis in
certain settings.
Conclusions
The key finding of this study is that autoantibody-
mediated arthritis in K/BxN mice can occur via a C5
activation pathway that requires neither C3 nor activat-
ing FcgRs, the two main effector mechanisms of IgG
molecules. Genetic deficiency of C3, C5, and/or FcRg
did not affect T-cell activation or autoantibody produc-
tion, indicating that the pro-arthritogenic activity of C5
is mediated by its conventional effector mechanisms
(likely C5a production). Our data further suggest that
thrombin or related proteases of the coagulation cascade
mediate C5 activation in the absence of C3 and FcRg.
Understanding how novel pathways of complement acti-
vation contribute to autoantibody-mediated arthritis and
other inflammatory disorders is expected to lead to new
therapeutic approaches.
Additional material
Additional file 1: IgG and C3 deposition in ankles of K/BxN mice
lacking C3 or C5 and lacking FcR©. Deposition of IgG (red, left panels)
and C3 (green, right panels) was determined by immunofluorescent
microscopy in K/BxN mice expressing or not expressing C3, FcR©, and C5,
as indicated in the left column. The key findings are that IgG is
deposited in each of the joints. As expected, C3 is absent in the C3-
deficient animal (A, lower right panel). Despite having decreased arthritis
severity, C3 is still detectable in the joints of the C5/FcR©-deficient
mouse (B, lower right panel). Slides were counterstained with DAPI (blue)
to detect nuclei. Original objective: 40x.
Additional file 2: Hepatic expression of prothrombin/thrombin is
upregulated in C3-deficient mice. Liver sections from C3-sufficient (left
panels) and C3-deficient (right panels) mice were stained with
monoclonal antibodies specific for prothrombin/thrombin (top panels) or
isotype control antibodies (bottom panels). Brown staining represents
bound antibody. The slides were counterstained with hematoxylin (blue).
Original objective: 40x.
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